Journal Browser
Volume | Year
News and Announcements
View All

Advances in Biomarkers for Sepsis

Submission deadline: 31 December 2023
Special Issue Editors
Andrea Piccioni
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Interests: novel biomarkers
Federica Manca
Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
Interests: internal medicine, emergency medicine
Special Issue Information

Sepsis is mainly caused by bacteria/viruses invading the body. The immune system overreacts, leading to multiple organ dysfunction. The mortality rate is as high as 40%, and the mortality rate of mild sepsis is 10%. Most bacteria/viruses invading the human body are Staphylococcus aureus, Streptococcus pneumoniae, Vibrio cholerae, etc. In recent years, COVID-19 may also lead to septicemia.

Despite extensive laboratory and clinical studies on sepsis, its diagnosis remains a clinical challenge. Timely diagnosis is crucial because delayed treatment leads to higher mortality, so treatment can be started early to ensure optimal results.

The occurrence of sepsis has activated many different biochemical and immune pathways, which are expressed through various molecular changes in human tissues. The detection and measurement of molecular concentration, which is called “biomarker”, may be an important diagnostic tool for clinicians to diagnose suspected sepsis. In addition, biomarkers can predict the prognosis of patients and may play a role in monitoring treatment response.

This special issue aims to collect evidence of inflammatory responses and metabolic characteristics in the pathogenesis of sepsis. This research project aims to make an important contribution to the literature and provide information for promoting the clinical research of precise medical prevention and treatment of sepsis based on biomarkers. We welcome the submission of original research, review, and comment articles from clinical and basic research.

Manuscript Submission Information

Author registration and submission: Please submit your paper along with a cover letter including the special issue title. Your paper will undergo a fair peer review and be published immediately after acceptance and will be available to an international audience.

Back to top
Global Translational Medicine, Electronic ISSN: 2811-0021 Print ISSN: TBA, Published by AccScience Publishing